29 October 2024NewsAmericasWendy Devine, Partner, Wilson Sonsini | Jesse Fecker, Vice President, Head of IP, Theravance Bio | Christina Susanto, Director of IP, Sutro Bipharma | Lawrence Kong, Executive Director, Legal and Intellectual Property, Addition Therapeutics
WATCH: Aligning innovation, regulation and IP protection
Experts from Wilson Sonsini, Theravance Bio, Sutro Bipharma, and Addition Therapeutics share insights on managing the intersection of innovation, regulatory compliance, and IP protection in the life sciences industry.
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Atif Choudhury at achoudhury@lifesciencesipreview.com
2 July 2026 A federal court has ruled in a dispute between a clinical trial technology company and a psychedelic drug developer over allegations of trade secret misuse during a bidding process.
30 June 2026 Sandoz has filed FDA applications for generic versions of Eli Lilly’s blockbuster drugs, marking an early step towards potential competition in the fast-growing GLP-1 market.
25 June 2026 The Federal Circuit has brought Paxlovid’s infringement case to an end, serving as a reminder that even minor changes to patent language can have major consequences.